2015


To access this material please log in or register

Register Authorize
2015/№5

Simultaneous inhibition of platelet and plasma hemostasis units: a novel strategy for secondary prevention of acute coronary syndrome

Chipigina N. S.
State Budgetary Educational Institution of Higher Professional Education, "N. I. Pirogov Russian National Research Medical University" of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: anticoagulants, secondary prevention, ACS, rivaroxaban

DOI: 10.18087/rhj.2015.5.2157

The review summarizes data for justification of using the “dual-pathway” antithrombotic strategy (i.e., anticoagulant plus antiplatelet treatment) after ACS and provides results of clinical studies on efficacy and safety of antiplatelet drugs in ACS.
  1. Collaborative overview of randomized trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994 Jan 8;308 (6921):81–106.
  2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345 (7):494–502.
  3. Wiviott SD, Steq PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015 Jul 18;386 (9990):292–302.
  4. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011 Dec;32 (23):2999–3054.
  5. Руда М. Я., Голицин С. П., Грацианский Н. А., Комаров А. Л., Панченко Е. П., Староверов И. И. и др. Диагностика и лечение больных острым ИМ с подъемом сегмента ST ЭКГ. Рекомендации Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика. 2007;6 (8 Прил 1):415–500.
  6. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr et al. 2012 ACCF / AHA focused update of the guideline for the management of patients with unstable angina / Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused upate): a report of the American College of Cardiology Foundation / American Task Force on practice guidelines. Circulation. 2012 Aug 14;126 (7):875–910.
  7. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33 (20):2569–619.
  8. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA et al. 2013 ACCF / AHA guideline for management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation / American Heart Association Task Forse on Practice Guidelines. Circulation. 2013 Jan 29;127 (4):529–55.
  9. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC / EACTS Guidelines on myocardial revascularization: the task force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35 (37):2541–619.
  10. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357 (20):2001–15.
  11. Wallentin L, Becker RC, Bugaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361 (11):1045–57.
  12. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Rardt H et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010 Nov;31 (22):2755–64.
  13. Moser M, Oliver CB, Bode C. Triple antithrombotic therapy in cardiac patients: more question than answers. Eur Heart J. 2014 Jan;35 (4):216–23.
  14. Reejhsinghani R, Loffi AS. Prevention of stent thrombosis: challen­ges and solutions. Vasc Health Risk Manag. 2015 Jan 27;11:93–106.
  15. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005 Jun 21;45 (12):2088–92.
  16. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and effect of thrombolysis. Circulation. 1998 Jan 6–13;97 (1):26–33.
  17. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994 Jul;90 (1):61–8.
  18. Andreotti F. The TIMI 9b and CUSTO IIb trials and the “Thrombin hypothesis”. J Thromb Trombolysis.1997;4 (3 / 4):311–3.
  19. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest.1990 Aug;86 (2):385–91.
  20. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med.1996 Sep 12;335 (11):775–82.
  21. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9b trial. Circulation. 1996 Sep 1;94 (5):911–21.
  22. Kottke-Marchant K, Bahit MC, Granger CB, Zoldhelyi P, Ardissino D, Brooks L et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes: the GUSTO-IIb haemostasis substudy. Eur Heart J. 2002 Aug;23 (15):1202–12.
  23. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction primary results of the CHAMP study. Circulation. 2002 Feb 5;105 (5):557–63.
  24. Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancen.1997 Aug 9;350 (9075):389–96.
  25. Brouwer MA, van den Bergh PJ, Aengevaeren WR, Veen G, Luijten HE, Hertzberger DP et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT) – 2 Trial. Circulation. 2002 Aug 6;106 (6):659–65.
  26. Van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet. 2002 Jul 13;360 (9327):109–13.
  27. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25307 patients. Eur Heart J. 2006 Mar;27 (5):519–26.
  28. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet. 2003 Sep 6;362 (9386):789–97.
  29. Christersson C, Oldgren J, Bylock A, Wallentin L, Siebahn A. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. J Thromb Haemost. 2005 Oct;3 (10):2245–53.
  30. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011 Nov;32 (22):2781–9.
  31. Hohnoloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial. Circulation. 2012 Feb 7;125 (5):669–76.
  32. Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012 Oct 6;2 (5):e001592.
  33. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012 Mar 12;172 (5):397–402.
  34. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015 Jan 13;131 (2):157–64.
  35. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjoth F, Rosenzweig M, Lane DA, Lip GY. Myocardial ishemic events in ‘real world’ patients with atrial fibrillation treated with dabigatan or warfarin. Am J Med. 2014 Apr;127 (4):329–36.
  36. Бражник В. А., Затейщиков Д. А. Обострение ИБС: баланс риска болезни и риска лечения. Consilium medicum. 2015;17 (1):30–5.
  37. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M et al. Apixaban, an oral direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 9;119 (22):2877–85.
  38. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25;365 (8):699–708.
  39. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet. 2009 Jul 4;374 (9683):29–38.
  40. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5;366 (1):9–19.
  41. Cavender MA, Gibson CM, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E et al. The effect of rivaroxaban on myocardial infarction in the ATLAS ASC 2‑TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2014 Oct 15. pii: 2048872614554109.
  42. Mega JL, Brounwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG et al. Ривароксабан у больных ИМ с подъемом сегмента ST после стабилизации состояния. Результаты исследования ATLAS ACS-2‑TIMI-51 (Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome – thrombolysis in myocardial infarction-51). Рациональная фармакотерапия в кардиологии. 2014;10 (2):245–52.
  43. Gibson CM, Chakrabati AK, Mega J, Bode C, Bassand JP, Verheugt FW et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol. 2013 Jul 23;62 (4):286–90.
  44. Bassard JP. Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis. Europrevention. 2014 Mar 20;9 (11):1333–41.
  45. Griffin JH. Blood coagulation. The thrombin paradox. Nature. 1995 Nov 23;378 (6555):337–8.
  46. Острый ИМ с подъемом сегмента ST ЭКГ: реабилитация и вторичная профилактика. Российские клинические рекомендации. CardioСоматика. 2014; (Прил 1):5–42.
  47. Руда М. Я., Аверков О. В., Голицын С. П., Грацианский Н. А., Комаров А. Л., Панченко Е. П. и др. Диагностика и лечение больных острым ИМ с подъемом сегмента ST ЭКГ. Кардиологический вестник. 2014;9 (4):3–60.
  48. Almendro-Delia M, Valle-Caballero MJ, Garsia-Rubira JC, Munoz-Calero B, Garcia-Alcantara A, Reina-Toral A et al. Prognostic impact of atrial fibrillation in acute coronary syndromes: results from the ARIAM registry. Eur Heart J Acute Cardiovasc Care. 2014 Jun;3 (2):141–8.
  49. Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. Plos One. 2011;6 (9):e24964.
  50. Rohla M, Weiss TW, Wojta J, Niessner A, Huber K. Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. Eur Heart J (Cardivasc Pharmacother). 2015;1 (3):191–7.
  51. Dewilde WJ, Oirbans T, Verheught FW, Kelder JC, De Smet BJ, Herrman JP et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet. 2013 Mar 30;381 (9872):1107–15.
  52. Lyp GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and / or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014 Dec 1;35 (45):3155–79.
Chipigina N. S. Simultaneous inhibition of platelet and plasma hemostasis units: a novel strategy for secondary prevention of acute coronary syndrome. Russian Heart Journal. 2015;14 (5):299–307

To access this material please log in or register

Register Authorize
Ru En